Preferred Label : bamlanivimab;
Obsolete resource : false;
MeSH hyponym : LY-COV555; LY3819253;
UNII : 45I6OFJ8QH;
Origin ID : C000711749;
UMLS CUI : C5421805;
CISMeF manual mappings
Currated CISMeF NLP mapping
MeSH term(s) associated for indexing
Pharmacological action(s)
Record concept(s)
See also (suggested by CISMeF)
Semantic type(s)
UMLS correspondences (same concept)
https://ansm.sante.fr/tableau-atu-rtu/bamlanivimab-700-mg-20-ml-35-mg-ml-solution-a-diluer-pour-perfusion-etesevimab-700-mg-20-ml-35-mg-ml-solution-a-diluer-pour-perfusion-en-association
2021
false
false
false
France
French
drug therapy, combination
summary of product characteristics
package leaflet
guidelines for drug use
infusions, intravenous
adult
aged
bamlanivimab
etesevimab
COVID-19
antibodies, monoclonal, humanized
---
Bamlanivimab - Potential Risk of Treatment Failure Due to Circulation of Resistant
SARS-CoV-2 Variants
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2021/75503a-fra.php
2021
false
false
false
Canada
French
pharmacovigilance note
antibodies, monoclonal, humanized
antiviral agents
risk
treatment failure
new coronavirus variant
drug resistance, viral
adult
adolescent
bamlanivimab
SARS-CoV-2
COVID-19
---
https://sante.gouv.fr//IMG/pdf/dgs_urgent_n2021_22_bamlanivimab_erratum_.pdf
2021
false
false
false
France
pneumonia, viral
coronavirus infections
bamlanivimab
drug information
hazardous substances
case management
Monoclonal antibodies
antibodies, monoclonal
Monoclonal antibodies
health facilities
risk-taking
monoclonal antibody
has patient
pandemics
COVID-19
antibodies, monoclonal, humanized
---
https://ansm.sante.fr/uploads/2021/03/16/20210315-atuc-bamlanivimab-etesevimab-put-2.pdf
2021
false
false
false
France
French
drug therapy, combination
guideline
health occupations
professional role
risk management
continuity of patient care
drug monitoring
infusions, intravenous
pharmacovigilance
information dissemination
drug prescriptions
Therapy cessation
adult
aged
antibodies, monoclonal, humanized
Etesevimab
Bamlanivimab
spike glycoprotein, coronavirus
adverse drug reaction reporting systems
bamlanivimab
bamlanivimab
pneumonia, viral
coronavirus infections
pandemics
pneumonia, viral
coronavirus infections
pandemics
coronavirus infections
COVID-19
COVID-19
antibodies, monoclonal, humanized
---
https://ansm.sante.fr/actualites/covid-19-lacces-aux-bitherapies-danticorps-monoclonaux-contre-la-covid-19-est-elargi
2021
false
false
false
France
French
drug information
drug combinations
antibodies, monoclonal, humanized
adult
Casirivimab/Imdevimab
Bamlanivimab
Etesevimab
guidelines for drug use
casirivimab
imdevimab
bamlanivimab
etesevimab
casirivimab and imdevimab drug combination
COVID-19
casirivimab and imdevimab drug combination
Product containing only casirivimab and imdevimab in parenteral dose form (medicinal
product form)
---
https://www.infectiologie.com/fr/actualites/combinaisons-d-ac-monoclonaux-en-traitement-du-sars-cov2_-n.html
2021
false
false
false
France
COVID-19
etesevimab
drug therapy, combination
infusions, intravenous
bamlanivimab
casirivimab
Casirivimab/Imdevimab
treatment outcome
imdevimab
scientific and technical information
---
https://ansm.sante.fr/tableau-atu-rtu/bamlanivimab-700-mg-20-ml-35mg-ml-solution-a-diluer-pour-perfusion
2021
false
false
false
France
French
package leaflet
summary of product characteristics
guidelines for drug use
pneumonia, viral
coronavirus infections
Bamlanivimab
Bamlanivimab
antiviral agents
antiviral agents
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
infusions, intravenous
adult
bamlanivimab
pandemics
COVID-19
---
Authorization of Bamlanivimab with English-only Labels for Use in Relation to the
COVID-19 Pandemic
https://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2020/74573a-fra.php
2020
false
false
false
Canada
French
English
drug information
canada
antibodies, monoclonal, humanized
adult
aged
adolescent
drug approval
drug labeling
infusions, intravenous
bamlanivimab
COVID-19
---
https://covid.cadth.ca/fr/traitement-fr/groupe-consultatif-sur-la-mise-en-oeuvre-du-bamlanivimab/
https://covid.cadth.ca/fr/traitement-fr/le-bamlanivimab-dans-le-traitement-de-la-covid-19-evaluation-critique-de-lanalyse-intermediaire-de-lessai-blase-1/
2020
false
false
false
Canada
French
English
drug information
drug approval
canada
antibodies, monoclonal
adult
adolescent
drug monitoring
continuity of patient care
technical report
Evidence-Based medicine
bamlanivimab
COVID-19
antibodies, monoclonal, humanized
---